Gronghui, November 26? UBS released a research report, saying that after a channel survey, it is believed that the development of CAR-T cancer immunotherapy in China is still in an early stage, and at present, the main treatments are concentrated in first-to second-tier cities with higher affordability. The bank quoted a doctor who pointed out that in addition to reimbursement, the average cost of patients before receiving CAR-T third-line treatment had reached 200000 yuan, and sales could only increase significantly if the average sales price of 2126.HK CAR-T dropped to between 150000 and 200000 yuan. The bank adjusted its peak sales forecast to lower its target price from HK $34.6 to HK $22, noting that the current valuation was undervalued and reiterating its "buy" rating.